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Abstract
Background: Patients with chemotherapy-related neutropenia and fever are usually hospitalized
and treated on empirical intravenous broad-spectrum antibiotic regimens. Early diagnosis of sepsis
in children with febrile neutropenia remains difficult due to non-specific clinical and laboratory signs
of infection. We aimed to analyze whether IL-6 and IL-8 could define a group of patients at low risk
of septicemia.
Methods: A prospective study was performed to assess the potential value of IL-6, IL-8 and C-
reactive protein serum levels to predict severe bacterial infection or bacteremia in febrile
neutropenic children with cancer during chemotherapy. Statistical test used: Friedman test,
Wilcoxon-Test, Kruskal-Wallis H test, Mann-Whitney U-Test and Receiver Operating
Characteristics.
Results: The analysis of cytokine levels measured at the onset of fever indicated that IL-6 and IL-
8 are useful to define a possible group of patients with low risk of sepsis. In predicting bacteremia
or severe bacterial infection, IL-6 was the best predictor with the optimum IL-6 cut-off level of 42
pg/ml showing a high sensitivity (90%) and specificity (85%).
Conclusion: These findings may have clinical implications for risk-based antimicrobial treatment
strategies.
Background
Infections are still the major cause of treatment-related
morbidity and mortality in cancer patients [1]. The malig-
nant disease and the intensive chemotherapy may cause
an impaired host defence to infection. Key factors are the
intensity and duration of neutropenia, but a decreased
function of granulocytes and disturbances of natural bar-
riers may substantially add to the risk of serious infections
[2]. Patients with chemotherapy-related neutropenia and
fever are usually hospitalized and treated on empirical
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intravenous broad-spectrum antibiotic regimens until the
patient is afebrile, the blood cultures are negative and the
absolute neutrophile count (ANC) has recovered to >
500/µl [3]. Patients without a documented clinical focus
of infection and without microbiological evidence for a
causative organism usually have a short duration of fever
and low risk of developing clinical complications. Unfor-
tunately, culture results become available only after 2 or 3
days and clinical information at fever onset that can be
used to establish prediction rules lacks sensitivity and spe-
cificity. There are a number of studies that have evaluated
diverse markers of inflammation as predictors of patients
subgroups with different types of infection [4-6]. If there
were parameters that could define a group of patients with
a low risk of sepsis, simplified approaches may include
early discharge from the hospital, intravenous treatment
as outpatients, or even the use of oral antimicrobial ther-
apy. This should reduce the risk of nosocomial infection
and development of resistant bacteria. Other advantages
would be cost savings and an improved quality of life for
these patients.
The inflammatory response reflects an ongoing collabora-
tion between tissue macrophages and mast cells, vascular
endothelial cells and circulating phagocytes. T-cells, B-
cells, natural killer cells and platelets are also involved in
the inflammatory response. The release of soluble inflam-
matory mediators plays a crucial role in activating and
coordinating this process. The proinflammatory cytokines
Tumor Necrosis Factor (TNF)-α and Interleukin (IL)-1
have a broad range of activities in the acute inflammatory
response. IL-6 is an extremely pleiotropic cytokine with
important effects on the growth and differentiation of T
and B cells, on the induction of the hepatic acute phase
response and enhancement of proliferation of hemat-
opoietic progenitor cells. IL-6 synthesis and secretion is
stimulated by IL-1. IL-8 is released from monocytes,
endothelial cells, neutrophils and many other cells in
response to IL-1 and TNF-α and activates neutrophils, T
cells and basophils. [7,8].
The aim of this study was to determine the value of serum
levels of IL-6, IL-8 and C-reactive protein (CRP) as predic-
tors for sepsis or prolonged fever in children with fever
and neutropenia due to chemotherapy at the start of a
febrile episode. We aimed to analyze whether IL-6 and IL-
8 could define a group of patients at low risk of septi-
cemia. This might lead to the identification of patients in
the future who can be discharged earlier from the hospi-
tal, or even treated under outpatient conditions.
Methods
Patients
The study was performed at the Department of Pediatric
Oncology and Hematology at the University Hospital
Freiburg, Germany. Sixty-nine patients with cancer or
haemotological disease with febrile neutropenia were
included in the study. Approval by an ethics committee
was not necessary at the time of the study. Informed con-
sent was given by the parents or patients. Their character-
istics are depicted in table 1.
Patients in good clinical condition and an expected dura-
tion of aplasia of less than five days were initially treated
with Ceftriaxone (80 mg/kg body weight/day). Patients in
poor clinical condition or an expected duration of aplasia
of five days or longer were treated with Ceftazidime (150
mg/kg body weight/day). Likewise, patients with acute
myeloid leukemia, high risk lymphatic leukemia, B-non-
Hodgkin's lymphoma, relapse of acute leukemia, or
patients undergoing bone marrow transplantation were
treated with Ceftazidime.
All together, 141 febrile episodes (defined as fever >
38.5°C once, or 38°C > 1 h) of 69 patients were analysed.
"Episode" was defined as the time between the first blood
sample and the last blood sample taken on the day on
which antibiotics were stopped. All patients were neutro-
penic at the onset of fever. Neutropenia was defined as
absolute neutrophil count below 0.5 × 109 /l. The blood
samples were taken within 24 hours since the start of fever
and than daily. The data from 123 of the 141 episodes
enrolled in the study could be analyzed. In 18 of the epi-
sodes, the first blood sample could not be taken within 24
hours since the start of fever. These episodes were
excluded from analysis. Nearly 75% of the patients expe-
rienced one episode, two patients six episodes. The dura-
tion of an episode ranged between one and 95 days, the
median duration was six days.
Three separate groups of febrile episodes were defined
(table 2). It was supposed that patients with a febrile epi-
sode up to three days without a positive blood culture and
without clinical signs of shock or a mirobiologically doc-
umented local infection had another cause of fever than
sepsis, for example fever due to chemotherapy or a viral
infection. Patients with a positive blood culture result
were classified belonging to the septic group (group is
called episep). Patients with a febrile episode of five days
or more were assigned to a separate group (group is called
epi5). On the basis of the long duration of the episode we
supposed that these patients had either a serious infection
or signs of clinical sepsis without microbiologically docu-
mented infection. Due to this group definition, there were
10 episodes that could not be classified to one of the
groups (duration of the episode four days with negative
blood culture). These episodes were not taken into con-
sideration while testing the differences between the
groups.BMC Infectious Diseases 2008, 8:28 http://www.biomedcentral.com/1471-2334/8/28
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Laboratory analysis
All patients were examined daily for clinical signs of infec-
tion. Prior to antibiotic therapy blood cultures, cultures
from urine and suspected lesions were taken. Additional
blood cultures were taken during the study period accord-
ing to clinical signs. During the febrile episodes complete
white blood counts (WBC), differentials, CRP, IL-6 and
IL-8 were determined daily. Cytokine concentrations in
the serum were measured by a fully automated random
access system (Immulite®) which allows the immediate
individual analysis of any blood sample at any time.
Statistical analysis
Nonparametric bivariate statistics were used for testing of
the association between variables. The Friedman test was
used to compare median-values of 3 or more groups in
related samples [9]. If this global-test was statistically sig-
nificant a pairwise post hoc test (Wilcoxon-Test) was per-
formed [10].
For unrelated samples the Kruskal-Wallis H test was used
to test the differences in the median-values of more than
2 groups (post hoc test: Mann-Whitney U-Test) [11,12]. P
values less than 0.01 were considered to indicate statistical
significance. To determine the cut-off-level with optimal
sensitivity and specificity Receiver Operating Characteris-
tics (ROC) were calculated [13]. Statistical analysis was
performed using SPSS for Windows 11.0.1 (SPSS Inc, Chi-
cago, IL).
Results
All together, 141 febrile episodes (defined as fever >
38.5°C once, or 38°C > 1 h) of 69 patients were analysed.
The data from 123 of the 141 episodes enrolled in the
study could be analyzed. In 18 of the episodes, the first
blood sample could not be taken within 24 hours since
the start of fever. These episodes were excluded from anal-
ysis. In Fig. 1 the comparison of IL-6 between the defined
groups on the first three days of fever is given.
On day 1, IL-6 is significant lower in group epi3 (median
21 pg/ml) than in group epi5 (median 146 pg/ml) or
group episep (median 326 pg/ml; p < 0.01). This differ-
ence exists also on day 2. On day 3, there is no difference
between the groups. There is also no statistically differ-
ence between groups epi5 and episep. In Fig. 2 the com-
parison of IL-8 between the defined groups on the first
three days of fever is given. On day 1, IL-8 is significant
lower in group epi3 (median 22 pg/ml) than in group
epi5 (median 97 pg/ml), and group episep (median 175
pg/ml; p < 0.01). This difference also exists on day 2. On
day 3, only a tendency can be observed (p = 0.01). There
is no statistically significant difference for IL-8 between
groups epi5 and episep. In Fig. 3 the comparison of CRP
between the defined groups on the first three days of fever
is given. On day 1, CRP is significantly lower in group epi3
(median 0.8 mg/dl) than in group epi5 (median 4.4 mg/
dl) and group episep (median 3.5 mg/dl; p < 0.01). This
difference can also be seen on day 2, but not on day 3.
Similarly, the maximum values of IL-6, IL-8 and CRP dif-
fer significantly between the groups. The values in group
Table 1: Patients characteristics
number of patients (n) 69
sex (m/w) 42/27
age at diagnosis (median, range) 7 8/12 yrs. (1 month – 20 years)
leukemia (n) 25
ALL 21
AML 1
JMML 1
AML-Relapse, after SCT 2
solid tumors (n) 39
brain tumor 5
bone tumor 4
Hodgkin's disease 3
NHL 10
others 17
hematological disorders (n) 5
after SCT 4
no SCT 1
ALL: acute lymphatic leukemia; AML: acute myeloid leukemia; SCT: 
stem cell transplantation; NHL: Non-Hodgkin's-lymphoma.
Table 2: Description of the different groups of episode
Group Description n duration of episode in days; median 
(range)
Epi3 duration of episode ≤ 3 days, blood culture 
negative
28 2 (1–3)
Epi5 duration of episode ≥ 5 days, blood culture 
negative
71 8 (5–95)
Episep documented Gram-negative or Gram-positive 
blood culture
14 10 (3–36)
Intermediate group (not included in the 
analysis)
duration of episode 4 days, blood culture negative 10 4BMC Infectious Diseases 2008, 8:28 http://www.biomedcentral.com/1471-2334/8/28
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epi3 (IL-6 21 pg/ml; IL-8 22 pg/ml, and CRP 0.8 mg/dl)
are significantly lower than in the two other groups (p <
0.01). Between the groups episep and epi5 no difference
is observed (episep: IL-6 569 pg/ml, IL-8 175 pg/ml, CRP
10.4 mg/dl; epi5: IL-6 268 pg/ml, IL-8 246 pg/ml, CRP 11
mg/dl).
To test which cut-off-level for IL-6 or IL8 would be useful
to seperate fever of unknown origin from sepsis, first the
group of children with documented sepsis is compared to
the two other groups (epi3 und epi5). From the ROC
curve, a cut-off value of 240 ng/l is calculated for IL6,
resulting in a sensitivity of 67%, a specificity of 75%, and
a positive predictive value (PPV) of 28%. For IL-8 a cut-off
level of 90 ng/l is found with a sensitivity of 67%, a spe-
cificity of 62%, and a PPV of 20%. Because of the low val-
ues for sensitivity und specificity, no clear separation
between the two groups can be made.
In the following analysis the group of children with sepsis
and the group of children with a longer episode of fever is
combined (episep + epi5), and compared to the group of
children with low-grade fever (epi3). In this analysis, a
cut-off value of 42 pg/ml for IL6 is found, resulting in a
sensitivity of 90%, a specificity of 85%, and a PPV of 94%,
meaning that in 94% of the cases patients with an IL6-
value at the first day of fever above the cut-off-level 42 pg/
ml will develop sepsis or a longer episode of fever. The
NPV (negative predictive value) is 77%, meaning that in
77% of the cases patients with an IL6-value at the first day
CRP (mg/dl) according to the different groups of episode at  the days of fever 1, 2 and 3 Figure 3
CRP (mg/dl) according to the different groups of epi-
sode at the days of fever 1, 2 and 3.
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of fever below the cut-off-level will not develop sepsis or
a longer fever period.
Thus, measuring IL6 at the first day of fever allows to iden-
tify a group of patients whith a high risk to develop sepsis
or a prolonged episode of fever. On the other hand,
patients with IL6-values below 42 pg/ml on the first day
of fever have a high chance to belong to a group of
patients with a short episode of fever.
For IL-8 and CRP the values for sensitivity, specificity and
PPV were less impressive. For IL-8 a cut-off of 30 pg/ml
results in a sensitivity of 87%, a specificity of 59%, and a
PPV of 84%. For CRP a cut-off of 1 mg/dl was associated
with a sensitivity of 83%, a specificity of 59%, and a PPV
of 86%, respectively.
Discussion
In this study we analyzed the significance of serum levels
of the proinflammatory cytokines IL-6 and IL-8 as well as
C-reactive protein as predictors for severe bacterial infec-
tion or bacterial sepsis in children with fever and neutro-
penia during cancer chemotherapy. We applied a new
method for the measurement of cytokines, a fully auto-
mated chemiluminescence immunoassay, which allows
the immediate random access analysis of blood samples.
Previous studies have established the value of cytokines
such as IL-6 and IL-8 to predict bacterial infection in the
neonate with high sensitivity and specificity [14]. Other
studies have used similar criteria, affirming their predic-
tive value in the setting of fever and neutropenia among
patients during cancer chemotherapy. De Bont et al.
showed that plasma levels of IL-6 and IL-8 can be used to
define a group with low risk of septicaemia among cancer
patients, aged between 1 and 66 years, with fever and neu-
tropenia [15]. Data reported by Lehrnbecher et al. showed
the potential usefulness of IL-6 and IL-8 as early indicators
for life-threatening infections in febrile cancer patients
with neutropenia [16].
In this study, it could also be shown that plasma IL-6 and
IL-8 levels can possibly be used to define a group with low
risk of septicaemia among children with fever and neutro-
penia. The sensitivity and specificity of each parameter at
different cut-off levels were analyzed to predict bacteremia
or severe bacterial infection among all febrile episodes at
the time of admission. In order to define a group with low
risk of septicaemia, three separate groups of febrile epi-
sodes were defined (Tab. 2). It was supposed that patients
with a febrile episode up to three days without a positive
blood culture and without clinical signs of shock or a
mirobiologically documented local infection had another
cause of fever than sepsis, for example fever due to chem-
otherapy or a viral infection. Patients with a positive
blood culture result were classified belonging to the septic
group. We chose the time period of 3 and 5 days, respec-
tively, because this is usually the time point where the
decision has to be made if antibiotics have to be kept,
changed or withdrawn. In our experience episodes of up
to 3 (and 5, respectively) days of antibiotics are very
unlikely to be associated with true septicemia or invasive
bacterial infection. Therefore, it was our intention to
define a group of patients with a probably low risk of
severe infection. There is a grey area between the low and
the high risk group. In order to achieve a high specificity
of the low-risk definition, this postulated grey area was
included into the high-risk group, and the cut-off level
was set accordingly.
In predicting bacteremia or severe bacterial infection, the
optimum IL-6 cut-off level was 42 pg/ml with a high sen-
sitivity (90%) and specificity (85%), the positive predic-
tive value was 94%. IL-6 was the best predictor, the other
parameters showed a lower sensitivity and specificity. The
optimum IL-8 cut-off level was 30 pg/ml with a high sen-
sitivity (87%) and a lower specificity (59%). The opti-
mum CRP cut-off level was 1 mg/dl with a sensitivity of
83% and a specificity of 59%. The group of patients with
loy-grade fever and a documented gram positive or gram
negative blood culture are small (28 and 14 patients
respectively), a larger group would e.g. reveal IL-8 to be
the most accurate parameter.
Lehrnbecher et al. found that either IL-6 or IL-8 might be
useful parameters in a febrile child with cancer and neu-
tropenia at the time of admission [16]. IL-6 and IL-8 levels
were higher in patients with either bacteremia due to
Gram-negative organisms or fungal infections than in
patients with febrile episodes without an identifiable
source. De Bont et al. also found that IL-6 and IL-8 were
highly correlated [15]. Addition of IL-6 to a model con-
taining IL-8, or vice versa, did not significantly improve
the fit. Engel et al. compared serum levels of procalcitonin
with IL-8, and showed that IL-8 was more sensitive and
specific than procalcitonin in the prediction of Gram-neg-
ative bacteremia [17].
In contrast, Fleischhack et al. suggested that procalcitonin
is a more useful diagnostic parameter in febrile cancer
patients than IL-6, IL-8 and CRP [18]. Strychjewski et al.
combined calcitonin precursors with interleukin-8 as a
marker of bacterial sepsis in febrile, neutropenic children.
IL-8 was increased in septic children compared with those
without bacterial sepsis but there were no significant dif-
ferences in the values of IL-6 between septic and nonseptic
patients. Using CTpr at 24 hrs in addition to interleukin-
8 at 48 hrs produced the best-fit models associated with
sepsis [19]. Kitanovski et al. suggested that IL-6 and PCT
are more sensitive and specific early markers of bactere-BMC Infectious Diseases 2008, 8:28 http://www.biomedcentral.com/1471-2334/8/28
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mia/clinical sepsis than CRP in children with febrile neu-
tropenia. Sequential determinations improved the
diagnostic accuracy of PCT, but not of IL-6 [20].
Hodge et al. simultaneously determined multiple
cytokines in childhood oncology patients with febrile
neutropenia and found increased IL-8 or IL-5 correlating
with culture-positive infection [21]. Nijhuis et al. used a
risk assessment model combining clinical parameters and
plasma interleukin 8 levels to define 3 risk groups among
outpatients with febrile neutropenia (children and
adults). Patients at low risk for bacterial infection did not
receive antibiotics [22].
Serum levels of CRP are commonly used to assess and
monitor the acute-phase response. Several studies found a
high sensitivity of serial CRP measurements but a low spe-
cificity, as it was shown also in this study [4,16,23,24].
Hospital treatment of all patients with neutropenia with
empirical intravenous broad-spectrum antibiotic regi-
mens at the first signs of fever has drastically reduced mor-
bidity and nearly eliminated mortality. For high-risk
patients, this treatment is appropriate considering the
possibility of rapid deterioration. But nearly two-thirds of
all children are treated without having a source of the
fever identified [25,26]. Antibiotic therapy is given for at
least 3 days or even longer, which results in the risk of
exposure to nosocomial pathogens and selection for
resistant bacteria or even fungal infections. For these
patients it would be of great interest to have a reliable
diagnostic marker to identify them belonging to a low-risk
group on day one of a fever episode. Studies that used fac-
tors like IL-6 or IL-8 to define a low risk group were often
determined after three days but there are also studies (e.g.
Oude Nijhuis et al) that determined a low risk group after
12 hours and studies that determined a low risk group
within 24 hours when using clinical parameters (e.g.
Aquino et al, Santolaya et al).
The factors used so far to define a low-risk group were
absolute neutrophil count, the absence of comorbidity
such as hypotension and respiratory compromise, the
duration of fever (at least 24 h afebrile), the type of malig-
nancy and disease status were the most important indica-
tors [27].
Studies published by Kern et al. and Freifeld et al. con-
cerning adult patients determined oral versus intravenous
empirical antimicrobial therapy for low-risk febrile
patients with neutropenia during cancer therapy [28,29].
The criteria to identify low-risk patients were the follow-
ing: they excluded patients who had received allogeneic
bone marrow or peripheral-blood stem-cell transplants,
those with acute leukemia, those in whom granulocytope-
nia was expected to last longer than 10 days and those
with shock or any other condition that required intrave-
nous supportive therapy or precluded oral intake of drugs.
They showed that oral therapy with ciprofloxacin plus
amoxicillin-clavulanate was as effective and safe as intra-
venous therapy. Further carefully designed studies are
needed to specify the conditions under which outpatient
therapy will be an acceptable choice. In any case, the
establishment of careful rules with each patient and fam-
ily is essential.
Conclusion
In the present study, plasma levels of IL-6 and IL-8
allowed to define a group with short duration of the fever
episode and a group with severe infection or even blood
culture positive sepsis. IL-6 was the best parameter. Fur-
ther studies are needed to answer the question whether
the observed results are of clinical relevance and might be
used for early discharge of a selected group of patients, an
outpatient therapy with antibiotics given once daily intra-
venously (e. g. Ceftriaxone), or even the use of oral anti-
microbial therapy. This may ultimately result in
substantial cost savings, reduced exposure to nosocomial
pathogens, it may improve the quality of life of the chil-
dren, and reduce the disruption of family life.
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